title: Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
authors.affiliation: Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Scott
authors.forename: K
authors.initials: K
authors.lastname: Sangkuhl
authors.forename: E E
authors.initials: EE
authors.lastname: Gardner
authors.forename: C M
authors.initials: CM
authors.lastname: Stein
authors.forename: J-S
authors.initials: JS
authors.lastname: Hulot
authors.forename: J A
authors.initials: JA
authors.lastname: Johnson
authors.forename: D M
authors.initials: DM
authors.lastname: Roden
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.forename: A R
authors.initials: AR
authors.lastname: Shuldiner
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy; D000483:Alleles; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine